Table I.
Characteristics of analyzed datasets.
| Dataset first author | Acronym | Samples | Assay/sequencing type | method | (Refs.) |
|---|---|---|---|---|---|
| Redova et al | MR | Blood serum of 15 RCC patients and 12 matched healthy controls | TaqMan Low Density Arrays | RT-qPCR | (20) |
| Wu et al | XW | A set of benign kidney specimens (n=10) and a 28-sample ccRCC training cohort, including localized (pT1; n=13) and metastatic (M1; n=15) tumor samples | Agilenta Human miRNA Microarray V2 | RT-PCR | (21) |
| Osanto et al | SO | 11 fresh frozen ccRCC and adjacent non-tumoral renal cortex pairs | Small RNA sequencing | Stem-loop PCR | (22) |
| Nakada et al | CN | 26 individuals, representing 16 CCCs, 4 ChCCs and 6 normal kidneys | Agilenta G4470A Human miRNA Microarray | RT-qPCR | (23) |
| Hidaka et al | HH | 10 cancer tissues and 5 adjacent non-cancerous tissues | TaqMan LDA Human MicroRNA Panel v2.0 | RT-qPCR | (13) |
| Weng et al | LW | Paired frozen and FFPE benign kidney (n=3 each) and ccRCC (n=3) specimens | Small RNA sequencing and MicroRNA Human Version 2 Microarray | RT-PCR | (24) |
| Gottardo et al | FG | 27 kidney specimens (20 carcinomas, 4 benign renal tumors and 3 normal parenchyma) | MicroRNA oligonucleotide microchips | – | (25) |
a
Agilent Technologies GmbH, Waldbronn, Germany. CCC, clear cell carcinomas; ChCC, chromophobe renal cell carcinomas; ccRCC, clear cell renal cell carcinoma; FFPE, formalin-fixed paraffin-embedded; RT-qPCR, reverse transcription-quantitative polymerase chain reaction.